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                                                     INTRODUCTION 
 
 Snakes are fascinating part of nature. Their colour, movement and 
secretive habits make them seem more mysterious than other animals. 
For people interested in wildlife, snakes are a wonderful introduction to 
the world of nature. There are over 3000 species of snakes in the world, 
of which more than 200 – ranging in size from 100mm long worm 
snakes to 6m long pythons – are found in India.1 Snakes occur in most 
habitats from warm seas to deserts, and from swamps, lakes and 
farmlands up into the mountains. These predators play a major role in 
the maintenance of the ecosystem. 
  India has been known as a land of exotic snakes. Here, 
snakes have been worshipped as Gods  for thousands of years. Even 
today, in Bathis Shirala, Maharashtra, during the harvest festival called 
‘Nag Panchmi’, freshly caught cobras are worshipped with flowers, ghee 
and money. Most of us flee at the sight of a snake. However, a group of 
people have based their living on these primitive reptiles. In south India, 
the Irula tribals, over years, have been supplying millions of snakes 
skins for export. As this trade has been banned today, they catch 
snakes for venom extraction, and this venom is used in the process of 
anti venom  production. 
Snakebite is a common emergency encountered in day-to-day practice. 
Morbidity and mortality due to snakebite is a preventable health hazard 
in the tropical and sub-tropical countries. In India, due to the prevailing 
climactic conditions, due to the fact that a major portion of the 
population is rural and agrarian, snakebite is a major health problem. 
Every year, 15,000 die out of 2,00,000 snakebites in India. The death 
rate is approximately 7.5%. However, this figure is based on hospital 
statistics. whereas in practice, most rural patients prefer treatment by 
traditionally healers and do not go to hospitals. 
                      Dr. Patrick Russell in 1796 (then aged 69) wrote from 
India of snakebite: “…… the progress of diseases, and succession of 
symptoms, had either not been attended to or were indistinctly 
recollected …….” His plea for the clinical observation remained largely 
unheeded for years until the landmark study in 1963 by Reid. Since 
then a number of studies have been carried out. 
  It is true that the effect of cobra bite kills the patients within 
minutes to hours – however, if managed sufficiently early with anti-
snake venom, the patient recovers soon. In the case of viper bites, 
which are more common, death occurs over days. Even in the absence 
of death, the morbidity is high. These factors necessitate aggressive 
and specific treatment. The effect of viper bites on the haematological 
system and their management still holds a lot of controversy. We have 
chosen a study on these haematological effects and response to 
treatment as our institute is situated in a primarily rural setting with a 
high inflow of cases, mainly viper bites. 
                                AIMS OF THE STUDY 
 
1. To assess the changes in coagulation profile following snake bite. 
2. To document the species of snakes that commonly cause 
coagulation abnormality. 
3. To study the common forms of systemic  bleed in snake-bitten 
individuals. 
4. To analyse the time intervals between the snake bite and onset of 
coagulation profile abnormalities. 
5. To correlate the clinical severity to the abnormalities of 
quantitative coagulation tests. 
6. To study the time taken for reversal of changes in coagulation 
profile to normal following anti-snake venom therapy. 
7. To find correlation between coagulation abnormalities, their 
reversal and the time interval between bite and starting of 
treatment. 
8. To look for the association between renal failure and alteration of 
coagulation profile. 
 
 
          
 
                             
                              REVIEW OF LITERATURE 
 
        TAXONOMY, IDENTIFICATION AND DISTRIBUTION OF 
SNAKES 
 There are about 2500 to 3000 species of snakes of which about 
500 belong to the five families of Venomous snakes, Atractaspididae, 
Elapidae, Hydrophidae, Colubridae [some species] and Viperidae.4  In 
India 236 different species of snakes are found out of which 50 species 
are reported to be poisonous.2 Among the non-venomous snakes only 
the giant constrictors are potentially dangerous to man – these include 
the South African and Asian pythons, and the South American 
anaconda 4. 
  Poisonous snakes prevalent in India belong to four families. 
 They are 
1. Elapidae – includes cobras & krait 
2. Viperidae (true vipers) – includes Russell’s viper & saw scaled 
viper. 
3. Colubridae ( pit vipers) – includes green pit viper. 
4. Hydrophidae (or) sea snakes.5 
 
In India, although 50 species belonging to these families are 
venomous, most are no threat to man. The only venomous snakes to 
be wary of are the “Big four” – COBRA, KRAIT, RUSSELL VIPER 
and SAW SCALED VIPER.2 
 
 COBRAS:  Two species of cobras are found in India, common     
cobra (Nalla or Nagu Pambu) and king cobra (Raja Nagam or Karu 
Nagam). Cobras vary in colour from black or dark brown to yellow 
white1,5.   The head is indistinct from the neck and the ribs in this region 
are movable and expand to form the hood. This hood on its dorsal 
aspect resembles a spectacle showing a connected  pair of rings. 
Cobras are often confused with Indian rat snakes (sara pambu) which 
have a much thinner neck and head and are about 3 feet longer than 
India Cobras. King Cobras are found in dense forests and are upto a 
length of 18 feet. They are usually black in colour. 
 
  KRAITS: Two species of  Kraits are commonly found in 
India. Common Krait (kattu viriyan or karuvelan pambu) and Banded 
krait (pattai kattu viriyan ). Common krait is steel blue or black with 
white bars on the back. Banded krait is larger and is jet black in colour 
with yellow bars. Kraits are usually found in pairs. 
 
  RUSSELL’S VIPER: (KANNADI VIRIYAN) : This is a 
larger snake measuring 6 feet and is stout, lazy looking and makes a 
loud hissing sound by expelling air through its large nostrils. It is brown 
or yellowish with dark round spots on the dorsum edged with white and 
black colour. 
 
  SAW SCALED VIPER: (SURUTAI PAMBU) :  A small 
snake (30cm long) with brown or grayish dorsum showing zig zag 
pattern. It has a distinct cross or lance mark on the head. The ventral 
scales are rough. They produce a rasping sound by rubbing their coils 
together. This snake is often confused with a non poisonous snake  
“ cat snake” (ponnai or ollai Pambu) which has a thin long tail, 
prominent eyes and a clear mark on the head. Most often a killed snake 
is brought by the patient and physician has to identify whether they are 
poisonous or not. Generally speaking non poisonous snakes have blunt 
tails, solid teeth, no fangs and semicircular ventral scales. Ventral 
scales do not completely cover the belly except in colubridae (rat 
snakes). But if the physician has a mental picture of the four common 
poisonous snakes it would be much easier for him to know which bite 
has to be given significance. 
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                GENERAL FACTS ABOUT SNAKES 
 
   Snakes are cold blooded animals without ears or 
tympanic membrances. They react to vibrations received through the 
surface on which they rest rather than air borne vibrations. Snakes do 
not have a distinct visual system and they do not readily assocate 
stationary objects with danger. Their sense of smell is the important. 
Most land snakes feed on mice, rats and frogs. Kraits and Cobras are 
exceptional in being mainly snake eaters. No one knows the life span of 
snakes in the wild. Longevity of some Indian snakes kept in zoos and by 
individuals include, Indian python : 34 yrs; Banded Kraits:11yrs; Indian 
cobras 21yrs; saw scaled &Russel viper: 10 yrs; . The south Indian 
tribals who have based their living on snakes are called ‘Irulas’. 
 
Epidemiological Features of Snake Bite 
  Documented reports of epidemiological studies of snake 
bite in India are few. Although the exact number of persons inflicted by 
snake bite is not known, it is estimated that about 2,00,000 persons are 
annually bitten by snakes in the country and about 15,000 of these are 
fatal7 In a study conducted in Tamilnadu, hospital records showed a 
mortality of 11.6%. According to a study by Sawai in 1974, 71% of the 
victims are found in the age group of 11-50 yrs and 75% of the victims 
were male. A safdarjung Hospital study showed 81.5% of victims to be 
field workers. 75% bite occurred outdoors; 88.6% of victims were from 
rural India 6. Incidence of snake bite in India shows a seasonal variation. 
In North India 70-80% of bites are seen in the warmer months may to 
October 6. while a study conducted in Calicut Medical College, Kerala 
showed a maxium incidence of complications also maximum during this 
period.8.  Sawai’s study in 1974 showed 68% of snake bites occurred in 
the evening and night; 32% in the morning and afternoon. 72% of bites 
were on the lower limbs; 25% on the hand and arm; and 3% were on 
the trunk. 
 
VENOM APPARATUS AND COMPOSITION 
 
  In certain snakes (poisonous) the paired salivary gland has 
assumed a very significant function (venom apparatus)6.They secrete 
venom, a powerful multipurpose enzyme fluid through the channeled or 
grooved teeth, the fangs6. venom can be injected from the bottom of the 
fang (viper) or by  an opening at the anterior aspect of the fang, a few 
millimeters above the tip4. (performance of the venom apparatus varies 
with different species)4. Palestine vipers in catching their prey inject 
lethal doses of venom at each of ten or more humans in rapid 
succession, the second or third victims were sometimes more 
envenomed than the first4. However Russell vipers appear to inject most 
of their available venom at first strike4 . 50% of Malayan pit viper bite 
showed little or no envenoming. This suggests that some snakes might 
be capable of biting defensively without injecting venom. 
  Snake venom is a complex fluid with powerful ingredients 
that acts to immobilize its prey. Hence snake bite on humans is a mere 
accident. Venom is faint, transparent, yellowish, slightly viscous and 
acidic. It is extremely heterogenous containing about 15 enzymes and 
10 non enzymatic  proteins and peptides and at least a dozen of other 
substances6. Various components of the snake venom have been 
mentioned in the accompanying table. Deoras in 1965 reported the 
lethal dose of venoms of common Indian poisonous snakes to be : 
cobra – 0.12g , Krait- 0.06g, Russell viper-0.15g and Echis carinatus – 
0.08g9a.  Variations in venom composition from species to species 
explains the varied clinical presentation of snake bite. There is a 
considerable variation in the relative proportions of different venom 
constitutions within a single species throughout the geographical 
distribution, at different seasons of the year, and as a result of aging 4,8 
Hyaluronidase is present in almost all snake venoms. It hydrolyzes the 
hyaluronic acid in interstitial spaces of the cells and connective tissue 
allowing further penetration of venom into surrounding tissues 6 
  Proteases in viper venom activate the mammalian clotting 
cascade by activation of factor Ix  or X. Ecarin a zinc metalloprotein 
activates prothrombin. 4. 
  
                          NON- ENZYMATIC COMPONENTS IN SNAKE  VENOM 
 
COMPONENT 
 
EFFECTS 
NEUROTOXIN: 
Cobra toxin 
Erabutoxin 
Alpha bungarotoxin 
 
Poly synaptic non- depolarising neuro muscular nicotinic Ach 
receptors.  To some extent cardio toxic , hemotoxic , and  anti 
coagulant. 
CERULOTOXIN: 
( KRAIT) Beta 
bungarotoxin 
 
Similar post synaptic block but without binding to receptors.  Pre 
synaptic motor nerve end blockade. 
HAEMORRHAGINS: 
(HR-1 , HR-2 ) 
(viperidae , crotolidae ) 
Direct distruption of vessel endothelium.  
 Pro coagulant effect :  Factor IX activation by cleavage of peptide 
bonds . 
Factor X activation by calcium binding to gamma glutamic residues 
in X with rapid change Xa. Direct pro thrombin activation by cleavage 
of peptide bonds by venom . 
Anti coagulant effects: by inhibition of platelet , clotting factors  and 
direct fibrinolysis. 
 
CARDIOTOXIN: 
(Naja naja) 
Neuro muscular blockage , hemolysis , cytotoxicity , cardiac arrest. 
                        ENZYMATIC EFFECTS OF SNAKE VENOM 
          ENZYME 
 
                                     EFFECTS 
ARGININE ESTER 
HYDROLASE 
 
Bradikinin release , interference with clotting. 
PROTEOLYTIC 
ENZYMES 
 
Tissue destrucion , some causes bleeding. 
COLLAGENASE 
 
Digestion of collagen. 
HYALURONIDASE  A 
 
Reduction of collagen  viscosity. 
PHOSPHOLIPIDASE  A 
 
Un coupling of oxidative phosphorylation 
PHOPHOLIPIDASE B 
 
Hydrolysis of lyso phosphorylation. 
PHOSPHODIESTERASE 
 
Inhibition of DNA , RNA , arabinose dreivative. 
ACETYL 
CHOLINESTERASE 
 
Catalysis of hydrolysis of Ach. 
5’ NUCLEOTIDASE Specific hydrolysis of mono esterase which links with  5’  
position of DNA , RNA , L-amino acid oxidase catalysis of 
amino acid oxidation. 
 
THROMBIN- LIKE 
ENZYMES 
Depression of fibrinogen levels. 
 Phospholipase A2, the most extensively studied of al venom 
constituents has damaging effect on RBC, platelets, leucocytes, skeletal 
muscle, Endothelium, presynaptic terminals and also has opiate-like 
sedative effect.4. 
  Polypeptides called neurotoxins also cause presynaptic 
inhibition by blocking acetylcholine release or post-synaptic inhibition 
blocking its action.4 
  Haemorrhagins (HR-1 and HR-2) cause disruption of 
basement membrane of vessels and cause bleeding into organs.6 
 
CLINICAL FEATURES:   
The clinical features of snake bite can be considered under the 
following three headings:- 
1. Local effects. 
2. Systemic effects 
3. Complications. 
1. Local effects: 
The limb bitten by the snake shows increased vascular permeability 
leading to swelling& bruising. Factors responsible include proteases, 
phospholipases, hyaluronidase and endogenous autocoids released by 
the snake venom like histamine and kinin. Venoms of some vipers 
cause a diffuse increase in vascular permeability causing pulmonary 
edema.4. Local tissue necrosis occurs as a result of the direct action of 
myotoxic and cytotoxic factors, ischaemia due to thrombosis, external 
compression by tight tourniquets or swollen muscles 4. Regional tender 
lymphadenitis is an important clinical sign, occurring early, and is toxin 
mediated. Local swelling is a valuable sign of viper bite to the extent 
that its absence excludes viper bite 9. Local swelling occurs rarely with 
the Asian cobra bite, but is not seen with Krait or sea – snake bites 9. 
 
2. Systemic features 
Fear and emotional reactions :  Whether the snake is poisonous or non 
poisonous, fright is a common symptom. Patient may appear 
semiconscious with cold,. clammy skin, feeble pulse and rapid shallow 
breathing.9 
Bleeding and clotting disturbances: These are commonly seen after 
viper bites. This is due to procoagulant activity leading to consumption 
coagulopathy, anticoagulant activity inhibiting coagulation factors or due 
to thromobocytopenia.4. In the absence of trauma these generally do 
not causes spontaneous bleeding. If it occurs it is usually attributed to 
direct actions of haemorrhagic toxins.4. Commonest haemorrhagic 
manifestation seen in a study done by virmani and dutt in Jammu was 
haematuria ,while for reid it was hemoptysis 10,11. Other common types 
of bleeding include haemetemesis and bleeding from gums, injection 
sites, and nose 10 . Discoid ecchymoses have been noted by reid in his 
studies 11. A few Australian land snakes can cause haemolysis.4 
Neurological disturbances:     Neurotoxic  polypeptides and 
phospholipases of snake venom cause paralysis by blocking 
transmission at neuromuscular junctions ( post synaptic for krait and 
cobra, responds to neostigmine).4,4a. This is characteristic of kraits, 
cobras and coral snakes. The early features would be prominent 
forehead wrinkles, then ptosis, external ophthalmoplegia and finally 
paralysis of bulbar muscle causing respiratory paralysis4. Some patients 
bitten by elapids or vipers are in a physiologically drowsy state in the 
absence of respiratory or circulatory failure probably due to release and 
binding of endogenous opiates.4 
 
Rhabdomyalysis :      Generalised rhabdomylysis with release of 
myoglobulin, muscle enzymes and potassium causes respiratory failure, 
hyperkalemia and occasionally renal failure (mainly seen in sea-
snakes).4 
 
3. Complications 
(i)  Hypotension/shock: The cause of shock following snake bite 
include 
• Pain shock due to vasovagal mechanisms. 
• Vasodilating autocoids and oligopeptides in viper venom inhibit 
the kininase enzyme leading to vasodilatation and shock 
• Life – threatening anaphylactic reactions in previously sensitised 
individuals within minutes of being bitten. 
• Hypovalemia from loss of blood and plasma into swollen limb or 
massive gastro intestinal hemorrhage. 
• Direct myocardial action of toxin can contribute to hypotension  
   ( cardiogenic shock). 
• Pulmonary edema due to multiple effects (myocardial failure, 
increased permeability of pulmonary vessels) also contributes to 
shock. 
 
ii. Renal Failure: 
`  Ischemia (due to hypotension and DIC), nephrotoxic 
effect of venom, pigment nephropathy associated with 
rhabdomyolysis and intravascular haemolysis contribute to the 
development of acute tubular necrosis, bilateral cortical necrosis 
and renal failure commonly seen with Russell viper.12. It is the 
commonest cause of mortality in viper bite.6 
 
Iii. Gangrene/necrosis: 
   It is reported to be of high incidence in the United 
States of  America and Japan following snake bite, but is rare in India.6 
PRINCIPAL FEATURES OF ENVENOMATION BY DIFFERENT 
FAMILIES OF SNAKES 
 
• Elapidae (krait   /   cobra)   -  principal manifestation is 
neurotoxity. Local blisters and necrosis can occur. Australian 
Elapides cause bleeding manifestation.4 
• Viperidae ( Russell viper / Saw scaled viper) -  local swelling, 
cellulitis, regional lymphadenitis and bleeding manifestations.4 
• Hyperphiidae (sea snake) – Rhabdomyolysis 4. 
• Colubridae : Bleeding manifestation and renal failure.4. 
 
 
INVESTIGATIONS  IN  A  CASE  OF  SNAKE BITE 
 
 1. Clotting Time:  Incoagulable blood is a cardinal sign of 
systemic envenomation by majority of vipers. For clinical purposes a 
simple all or nothing test of blood coagulablity is adequate 4. A few 
milliliters of blood taken by venepuncture are placed in a clean dry test 
tube.4. More sensitive tests like prothrombin time and Fibrin 
Degradation products are not used routinely and are indicated only in 
special situations.4. Though snake bite is associated with 
thrombocytopenia, platelet count is not routinely needed until patient 
develops bleeding.  
 2. Blood Urea , Serum Creatinine and Electrolytes are indicated          
to detect development of Renal failure.4 
     3.Urine Examination for red blood cells.4. 
     4.White Blood cell count – Leucocytosis above 20,000 indicates 
severe envenomation 
     5.Packed cell volume is done if patient develops bleeding. 
          6.Additional Investigations: Done only in specific  conditions. 
 
- Rhabdomyolysis (Sea Snake) – Rise in myoglobulin 
and creatine phosphokinase. 
- Renal failure – PH, PCo2, Bicarbonate 
estimation,urine sodium 
- Shock (Cardiotoxin) – Electrocardiogram. 
- Pulmonary Edema – Chest X-ray. 
 
IMMUNO DIAGNOSIS 
 
   Enzyme linked immunosorbent assay is a very 
important tool for studying both the epidemiological and clinical effects 
of snake bite in humans. In places where specific anti snake venom is 
available against each species, if the snake is not brought along with 
the victim for identification, immuno detection of specific snake venom 
antigen in body fluids of  the patient will help in management.12 It has 
been proved by ELISA that effects of envenomation depend up on 
hours ( i.e, blood venom level x time elapsed between bite and 
institution of treatment) rather than blood level of venom.13. Immuno 
diagnosis kits are unlikely to be of practical help unless their present 
cost is substantially reduced and speed of diagnosis is increased 14. 
Studies in Liverpool are in progress to increase the rapidity of assay to 
provide specific diagnosis within 10 minutes of sampling 12.. ELISA  by 
detection of snake venom antibody can be used for retrospective 
diagnosis of envenoming in epidemiological studies.14. 
 
GRADING 
   Grading of the effects of viper bite has been done by 
different authors in varying patterns. The grading used by Reid in his 
study included both local and systemic effects in grading bites as those 
with nil, mild, moderate and severe emvenomation.11. In an Indian study 
this grading system was found to be complex and not very useful. 
  
 A much simpler manner of grading would be:- 
 Nil – no local cellulites \ lymphadenitis ; CT normal 
 Grade I – local cellulites + regional adenitis; CT normal 
 Grade II – CT prolonged +/- local signs 
 Grade III – CT prolonged + systemic features like bleeding and        
shock.15. 
                                               MANAGEMENT 
General Measures: 
 
• Reassure the victim 4 
• Immobilize the bitten limb using a splint or sling  
• Cauterization, incision and drainage, amputation, usage of venom 
pumps, instillation of chemical compounds and electric shock locally 
are all to be avoided as these will cause uncontrolled bleeding from 
the site and damage of nerves and vessels, leading to necrosis.4. 
• Use of tourniquets are controversial, dangers of their application 
include ischemia and gangrene, damage to peripheral nerves and 
increased local effect of venom. But in case of cobra or sea snake if 
medical therapy is likely to be delayed a firm crepe bandage can be 
applied. 
• Inj. Tetanus toxoid should be given. 
 
Specific therapy: 
ANTISNAKE VENOM THERAPY 
 
INDICATIONS: 
Distinction of poisonous from non-poisonous snake is often difficult, and 
is not usually important for the clinician. It is known that about 15 drops 
of viper venom can be fatal to an adult and 3 drops of cobra venom 
could be lethal, and that one drop of sea snake could kill 5 men. 
Fortunately human bite is a defensive reaction which rarely results in 
much venom being injected. Following poisonous snake bite more than 
half of victims will have minimal or no poisoning. Hence poisonous 
snake bite is not synonymous with snake bite poisoning. So even 
though the snake is identified as poisonous. Or there are bite marks, 
treatment should be given only if there are signs of envenomation. 
Antisnake venom itself can be fatal and it is a costly drug with limited 
supply.9 
 
CLINICAL INDICATIONS 
 
- Hemostatic abnormalities 
- Neurotoxicity 
- Generalized rhabdomyolysis 
- Definite evidence of local envenomation. 
 
CONTRAINDICATIONS: 
 
   There is no definite contraindication as Anti snake 
venom is the only specific therapy for snake bite. Atopic patients and 
those who had reaction to equine antiserum on previous occasions 
have an increased risk of developing severe antivenom reactions. It can 
be ameliorated by pre-treatment with adrenaline, anti-histamine and 
corticosteroid.4 
 
TYPES OF ANTI SNAKE VENOM: 
  Mono – specific forms are more effective and less likely to 
cause reactions than polyspecific antivenom. In most developing 
countries only a single polyspecific antivenom is available14. In India 
ASV is produced by Haffkine Institute, Bombay, and Central Research 
Institute, Kasauli. It is produced by hyperimmunizing horses against the 
common four poisionous snake (Cobra, Krait, Russell’s and Saw scaled 
viper).1 
 
DOSE OF ANTI- VENOM: 
    The dose schedule for polyvalent and 
monovalent antisnake venom varies. We know the lethal dose of Cobra 
is 0.12g, Krait – 0.06g, Russell viper – 0.15g, Echis carinatus- 0.08g. 
Poly valent anti-  snake venom 1 ml neutratilses 0.6mg of cobra venom, 
0.45mg of Krait, 0.6mg Russell viper and 0.45mg of Saw Scaled viper 
venom. Based on this if the poisonous snake is known , dose of anti 
snake venom can be estimated theoretically. But practically it is not 
applicable as amount of venom injected in each patient and by each 
bite varies. And invitro studies do not correlate with invivo results. 
Based on the results of a number of studies the dose of anti snake 
venom conventionally recommended as initial dose if snake is known is 
: common krait – 100ml of Haffkine polyspecific antivenom; Russell 
viper -100ml, Indian Cobra -100ml and Echis Carinatus -100ml.4. If the 
snake is not known the recommended amount of anti snake venom 
given based on clinical signs is 50ml, 100ml, and 150ml for grades I to 
III. For patients presenting with neurotoxic features initial dose of ASV 
given in 100ml.15. 
 
  The apparent serum half-life of antisnake venom in 
envenomated patients ranges from 26 to 95 hours depending on how 
they are prepared4 .Though it clears the venom from the circulation 
immediately, the clinical effect on clotting restoration occurs usually 
after four hours. Thus if dose has been adequate clotting time should be 
normal by 6 hrs 4,16.. Neurotoxic signs improve within 30 mins but may 
take several hours. A second dose is given if neurological features 
persist for more than 30 minutes. Dose of ASV is the same for adults 
and children.4 
  There is controversy about how long after envenomation 
Anti – venom therapy is still effective. Carrison et al claim that it is most 
useful if given within 4hrs, less if delayed for 8 hrs, and doubtful if given 
after 24hrs 17 However, Dwivedi et al have reported therapy with anti-
snake venom to be beneficial even after 8 days and state that there is 
no fixed time limit.18. 
 
MODE OF ADMINISTRATION: 
 
Local Injection:  If it were possible to inject anti-venom locally at the 
site of bite within a few minutes, necrosis might well be prevented. But 
in practice this is virtually never possible and therefore is not 
advocated.9 
 
Intravenous injection:  It is the most effective route. An infusion 
of anti-snake venom mixed with isotonic fluid is given in 1:3 dilution. It is 
given over 30-60 minutes, initially starting with 10-15 dps/mt and then 
increasing the dose 4. ASV can also be given direct intravenous bolus. It 
was found there is no difference in reaction between the two methods.19 
 
ANTIVENOM REACTIONS AND TESTDOSE 
 
  Anti snake venom therapy is complicated by 3 types of 
reaction. 1. Early (Anaphylactic), 2. Pyrogenic, 3. Late Serum sickness 
type reaction. 
 
  Early anaphylactic reaction was initially thought to be IgE 
mediated. However, in most there is no prior exposure to serum. Skin 
test dose reactions do not correlate with the incidence of reactions 
occurring during ASV administration.4,19 Complement activation is also 
implicated, but not proved.19 Clinical features include itching, utricaria, 
fever, tachycardia, palpitations, nausea, and vomiting. Early reactions 
are managed by 0.5ml of 0.1% adrenaline sub cutaneous and 
chlorpherneramine malete 10mgIV.4. Pyrogenic reactions results from 
contamination of anti- snake venom with endotoxin like compounds. 
High fever occurs which is treated with paracetomol.4 
 
  Late serum sickness reaction develops 5-24 days later, 
characterized by fever, itching, urticaria, arthalgia and 
lymphadenopathy, and is treated with chlorpheneramine 2mg four times 
daily or prednisolone 5 mg four times daily for 5 days.4. 
 
  The role of the intra dermal test with 0.2ml of ASV, though 
widely followed, is controversial. According to some authors, this test 
only delays the onset of definite therapy and has no role in the 
prediction of early or late Anti- snake venom reactions.4,19 
 
Other supportive measures 
• Neurotoxic effects – Artificial Ventilation. 
Intravenous neostigmine 0.5mg given at half hourly interval 
for five injections. This is followed by same dose at 
increasing intervals of 2 to 12 hours according to 
neurological recovery. Each dose of neotigmine is 
preceded by 0.6g atropine 6 . Shock- Plasma Expanders, 
Dopamine infusion, Steriods are used.4. 
 
• Renal Failure – During initial oliguric phase (less than 
400ml/24hrs) dopamine infusion at the rate of 
2.5microgr/kg/minute or diuretics are used. In established renal 
failure, dialysis is indicated.4. 
• Local infection: Intra compartmental syndrome – broad spectrum 
antibiotics are used. Blisters are best left undisturbed. Slough 
should be excised. Swelling of muscles within tight fascial 
compartments may raise the tissue pressure leading to impaired 
perfusion and ischemia. In these circumstances fasciotomy is 
indicated. It should be done only after blood coagulopathy has 
been treated. 
• Steroids are advocated in both patients presenting with bleeding  
tendencies with neurological manifestations (Hydrocortisone 50 to 
100mg I.V 8th hrly). However, its use remains controversial.20. 
• Heparin : Some studies show that if heparin 10,000 units is given 
intra venously stratum followed by 5000 units 8th hrly IV and 
continued for 48 hrs it is useful in the prevention of DIC.21 Yet, 
other studies have shown it to be ineffective and worsening 
bleeding.14. 
• Fibrinogen infusions are not helpful.14 
• Blood Transfusion: Helps in viper bite shock secondary to 
bleeding and also helps in the management if specific antivenin is 
not available. 
 
 
HEMORRHAGIC AND BLOOD COAGULATION DISTURBING  
 ACTIONS OF SNAKE VENOM. 
 
HISTORICAL REVIEW: 
 
   The effect of snake bite are of  two main kinds 
neurotoxic and hemorrhagic. In the course of history people have been 
impressed by the dramatically rapid lethal action of neurotoxic venoms, 
classically illustrated by Cloepatra’s suicide. Hemorrhagic effects of 
snake bite have also been known for thousands of years. Two 
hemorrhagic snakes in the North East are still called by Biblical names 
‘TSEFA’ and ‘EF’. The occurrences of snake bite hemorrhage in 
antiquity is similarly indicated by beliefs of certain primitive people 
associating menarche and snakebite 22.Two hundreds years ago 
Fontana (1787) noted that blood remained fluid in animals killed by 
viper bite. Mitchell (1860) reported the same phenomenon following 
American Pit vipers. Lamps (1901) reported the same with Russell viper 
bite. Mellan (1909) showed snake venom causes defibrination. Lewis 
(1956) experimentally classified snake venom into fibrinolytic, thrombic, 
thromboplastic and fibrinogenolytic categories. 
 
 PATHOGENESIS OF SNAKE BITE HEMORRHAGE: 
 
   The pathogenesis of snake bite hemorrhage involves 
coagulation disturbances by venom anti-coagulants or coagulants, 
thrombocytopenia & vessel wall damage caused by venom 
hemorrhagins.   
 
IN VITRO ACTION 
   Venoms may be broadly characterized by their 
effects on human or animal blood as coagulant or anti-coagulant. The 
distinction still holds in the literature although the assignment of a snake 
venom to one of these groups is often difficult in that the same venom 
may have both activities in vitro according to the concentration, method 
of collection, geographical area, season and method of storage.22 
 
(ii) Coagulant activity 
  
 
                 SNAKE VENOM  AND  THE  COAGULATION  
PATHWAY 
 
 
 
XIII 
VIII VI
 
-pro coagulant 
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venom ( clotting 
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 --anti coagulant 
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venom (cloting 
factor inhibition. 
Prothrombin-thrombin conversion. 
 
• FACTOR X ACTIVATION: 
 
     Russells Viper, Echis colorstus, Naja 
Nigricollis and various snake venoms promote prothrombin to thrombin 
transformation. The Coagulation Biography of Russell Viper Venom 
published by Macfarlane 1967 used venom for clot promoting activity of 
hemophilic patient blood applied as local hemostatic. Mechanism of 
prothrombin to thrombin conversion follows factor X activation.22. Factor 
X is activated by active factor VIII. It is said that Russell Viper venom 
resembles factor VIII.23. 
 
• DIRECT PROTHROMBIN ACTIVATION: 
 
     Block demonstrated lack of participation 
of factor X in thrombin formation induced by Tiger snake venom.24. It 
was found to activate prothrombin directly. 
 
• FIBRINOGEN – FIBRIN CONVERSION: 
               Von Klobusitzky isolated a potent coagulation fraction which          
he designated as “ Hemocoagulase”.25. A commercial preparation of 
venom coagulant “Repltilase” had similar properties. Its activity is similar 
to that of thrombin. Coagulant preparation “BOTHROPASE” is obtained 
from Bothrops Jaramaca Venom. 
 
(iii) ANTI COAGULANT ACTIVITY: 
 
1. Inhibition of prothrombin – thrombin conversion and other 
clotting factors. 
     Naja naja (Cobra) venom has exclusive 
anti coagulant activity by inhibition of prothrombin to thrombin 
conversion. Other anti coagulant activity of venoms include inhibition of 
factor V, VIII, IX reversibly. Phospholipase components of the venom 
could also lead to destruction of the clotting factors.22 
 
2. Fibrinogenolytic activity: Echis coloratus venom has 
fibrinogenolytic action at low concentration.26,27.while naja 
naja nigricolis is coagulant at high concentration and 
fibrinogenolytic at low concentration.26,27. 
3. Fibrin stabilizing factor inactivation: Echis coloratus venom is 
demonstrated to inactivate fibrin stabilizing factor in plasma 
independently from clotting process.22 
4. Other Mechanisms: The anti coagulant action of many 
venoms is still controversial. Some studies have shown 
Russell Viper venom acts only indirectly and not directly. It is 
said to act by releasing heparin like anti coagulant factors.22 
 
(iv) FIBRINOLYTIC ACTIVITY: 
Most of the venoms which are fibrinolytic are also fibrinogenolytic. 
 
(v) ACTION ON PLATELETS 
 
 Echis corolatus venom at high concentration lyses isolated 
platelets and liberated from them pyro phosphatase. Bothrops reptilase 
clotted platelets and fibrinogen. It produces loose platelet aggregates 
and releases platelet serotonin and adenine neucleotide. 
 
IN VIVO ACTION 
 
(A) Disseminated Intra Vascular Coagulation 
 
     Incoagulability of blood in animals dying 
from viper bite was mention in eighteenth century by Geoffroy (1737) 
and Fontana(1767). Its now generally accepted that the incoagulability 
produced by venom is primarily due to intra vascular coagulation. The 
mechanism of induction of intra vascular clot varies with different 
species. As already discussed above, it occurs mainly by the direct 
conversion of fibrinogen to fibrin or prothrombin to thrombin or factor X 
and XII activation by the venom.22. Direct pathological evidence for intra 
vascular clotting in humans is a demonstration of intra vascular clot. But 
their absence on autopsy does not rule out disseminated intra vascular 
coagulation as fibrinolysis can occur in the postmortem period. So the 
demonstration of a clot depends on the time between venom injection, 
dose of venom and the time of autopsy.28. 
 
 (B) Primary fibrinolysis In some cases it was found that when 
the blood was left to stand in a test tube for sometime it resulted in 
formation of a clot which then lysed after few minutes. This led on to the 
study of any other mechanism other than disseminated intra vascular 
coagulation being responsible for bleeding abnormality. A suggested 
mechanism was the direct fibrinogenolytic activity of venom. 
 
     The importance of knowing whether 
primary fibrinolysis acts in a significant manner in snakebite coagulation 
disturbances is of practical therapeutic importance. In case the 
coagulation disturbance is primarily DIC early stages would be 
benefited by heparin therapy (while in case of primary fibrinolysis the 
condition will be worsened by heparin). The points used for 
differentiation between primary fibrinolysis and DIC are listed in the 
accompanying table. 
  PRIMARY 
FIBRINOLYSIS 
               DIC 
INCIDENCE  
 
Exceedingly rare Fairly common 
PLATELET COUNT 
 
Normal  Low  
FIBRIN MONOMERS  
(PROTAMINE TEST) 
Negative  Positive  
FIBRIN DEGRADATION  
 
Very large amount  Variable amount 
CLOT LYSIS Very rapid after formation of 
clot 
No clot formation / variable 
PERIPHERAL SMEAR Normal  Fragmented RBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies in India have produced varying results. In a study conducted by 
Mohapatra and Nayak in 43 cases of Viper Bite Disseminated 
Intravascular Coagulation was the predominant coagulation 
abnormality.30 
 
     In another study by Saini, Sharma on 
thrity cases of viper bite, primary fibrinolysis was seen as the 
predominant change. Majority of studies have proved primary 
fibrinolysis as a less important mechanism.31. 
 
 
(c) Inactivation of Fibrin Stabilising Factor 
 
     Though in vitro inactivation of fibrin 
stabilizing factor following Echis coloratus has been demonstrated, in 
vivo inactivation is mainly a consequence of intravascular clotting.22 
 
        (D)Thrombocytopenia 
 
   It is known to accompany clinical and experimental 
defibrination. Apart from the fact that the platelets are trapped in 
intravascular clots venom factors (possibly phospholipase A) contribute 
to platelet damage. Clinically even in those cases in which 
thrombocytopenia is a feature, the hemorrhage of snake bite lacks the 
characteristics of thrombocytopenia in that petechiae are absent22. It is 
now concluded that thrombocytopenia is not the primary cause of 
envenomation hemorrhage but may be a aggrevating factor.22. 
 
 
(vi) Hemorrhagins 
 
   Incoagulability without hemorrhage was observed 
both clinical and experimentally in a few cases.11,12. This led to the 
assumption that hemorrhage in snake bite also occurs due to 
mechanisms other than coagulation disturbance. This led to the 
discovery of vessel wall damaging factor termed hemorrhagin in the 
snake venom.22. Earlier studies by Flexner found that these toxins 
cause rents in the vessel wall.32 Fulton has observed initial arteriolar 
constriction with sluggish circulation and subsequently red cells spurting 
through the vessel wall one by one without apparent damage of 
endothelium. It was concluded red blood cells spurt through pores 
developing in the region of the inter- endothelial substance. 
 
(vii) Supression of Fibrinogen formation 
 
   Snake venom is said to inhibit fibrinogen formation in 
the liver but this is not well established.11. 
 
ALTERATION IN COAGULATION PARAMETERS IN A CASE OF 
SNAKE BITE 
 
 
 
     Till today the main information for us 
about alteration in coagulation profile is based on the study by Reid. In 
his study 97 patients admitted following bite of Malayan Pit viper with 
features of envenomation were observed. Of these 54 were treated with 
Anti-Snake Venom and 43 where treated symptomatically as Anti-
Venom was not available. From both of the above groups 29 selected 
patients were studied for changes in coagulation parameters. A similar 
study was conducted in India by Mohapatra following viper bite in 
Orissa.30 
 
 
 
 
 
 
CLOTTING TIME 
 
  In Reid’s study all the cases had prolonged clotting time. 
The quality of the clot was also assessed by making the blood stand in 
a test tube undisturbed for 72hrs. they were graded as follows:- 
 
Grade 1 – Normal – cell deposits at the bottom of test tube do not rise 
above the bottom curve of the tube. Clot formed was about 50% of 
original whole blood volume. 
 
Grade 2 – Slight Defect – cell deposits increased above the bottom 
curve of the tube upto30% of original whole blood volume. Clot size 
diminished in proportion. 
 
Grade 3 – Moderate defect – cell deposit is 30% to 50% of original 
volume. Clot size is about half the size of a contracted normal clot. 
 
Grade 4- Severe Defect- cell deposit is 50% or more of the original 
volume. Clot size is  A Small speck. 
 
Grade 5- No clot. 
 
 It was found that in all cases of envenomation clot quality was 
abnormal from Grade -2 to Grade -5 with clot lysis maximum within 5 
hrs.(Normal is by 72hrs).11 In the Indian study clotting time was 
prolonged in 95% cases while clot quality was abnormal in all cases. 
5% cases with normal clotting time had prolonged thrombin and 
prothrombin time.30. 
 
BLEEDING TIME AND TOURNIQUET TEST: 
 
  Ten percent cases showed prolonged bleeding time in the 
Orissan study while Reid’s study showed only 5% prolongation. 
Tourniquet test was positive in 4% cases.11,30 
 
THROMBIN TIME / PROTHROMBIN TIME / ACTIVATED PARTIAL 
THROMBOPLASTIN TIME: 
 
  Thrombin time and prothrombin time were prolonged in 
both the studies. Activated partial thromboplastin time done only in the 
orissan study also showed prolongation in all cases.3,33. 
 
 
 
 
EUGLOBULIN LYSIS TIME: 
Done to diagnose primary fibrinolysis, it was positive only in 5% cases. 
But a study by Saini to differentiate DIC from primary fibrinolysis by 
Euglobulin lysis time, protamine Sulphate Test showed 90% positivity 
suggestive of primary fibrinolysis.30,33. 
 
FIBRIN DEGRADATION PRODUCT: 
  It was found to be elevated in all cases of envenomation.30 
 
FIBRINOGEN: 
  It was invariably low ranging from 10 to 160 mg/100ml in all 
cases.11,30 
 
PLATELET COUNT: 
 
  Count was 1 lakh and less in 93% cases. Reid’s studies 
showed a platelet count reduction in 95% cases. Saini’s study showed 
only 10% cases with reduction in platelet count.33 
 
: 
 
   
 
NATURAL COURSE OF RETURN OF COAGULATION PROFILE TO 
NORMAL 
 
  It was found that in those cases where anti-venom was not 
given despite moderate or severe systemic poisoning, coagulation 
defects persisted for an average 15 days ( range 6 to 26 days)11.( In the 
Indian study severe envenomation changes reverted back to normal in 
7 days and cases of mild envenomation in 2 to 3 days. 
 
 
CHANGE IN COAGULATION PROFILE FOLLOWING ANTI SNAKE 
VENOM ADMINISTRATION: 
 
   It was found that with specific anti-snake venom 
therapy correction of coagulation defect was remarkably rapid 
regardless of time elapsing between bite and anti-venom therapy11.. 
When fixed, adequate amount of anti-snake venom was given in cases 
of Malayan pit viper coagulation returned to normal on average in 9hrs. 
( range 2 to 18 hrs ). Relapse of coagulation abnormality was not found 
when adequate high dose was given initially. In case where low doses 
were used relapse of abnormal coagulation parameters after reverting 
to normal was noted.In 11patient following Haffkine polyvalent Anti-
snake venom it took 24 – 48 hrs to revert to normal. Clot quality, 
bleeding and clotting time, prothrombin fdtime, activated partial 
thromboplastin time reverted to normal in 57.9% cases in 24 hours, 
95% cases in 48 hours. Thrombin time, fibrinogen and platelet count 
took 3 -4 days to revert to normal.11,30. 
 
 
CHANGES IN COAGULATION PROFILE FOLLOWING BLOOD 
TRANSFUSION AND FIBRINOGEN INFUSION: 
 
   Although blood transfusion improved the general 
condition of the patient if shocked or anaemic it did not shorten the 
duration of coagulation defect.11. With fibrinogen infusion coagulation 
profile temporarily reverted to normal only to return in a more severely 
abnormal form. 
 
   In conclusion the alteration in coagulation 
parameters in a patient bitten by a poisonous snake occurs by multiple 
mechanisms, the principal one being DIC, and the best way to correct it 
is with antisnake venom therapy. 
 
 
 
 
                  M A T E R I A L   A N D   M E T H O D S 
  
 
STUDY POPULATION 
 
   This study was undertaken in Thanjavur Medical 
College Hospital in the period between july 2007 to October 2008 . 
Patients selected were among those admitted to the general medical 
wards following snake bite. 
 
SELECTION CRITERIA 
 
    Patient giving history of bite with definitive 
evidence of snake bite in the form of local cellulites, regional lymph 
adenitis and / or prolonged clotting time (taken as suggestive of viper 
bite) were considered for the study. Patients presenting with neurotoxic 
manifestations were not considered for the study. Patient having local 
swelling due to tourniquet application and local native treatment were 
again not considered for study. 
 
 
 
 
BASIC INVESTIGATION 
For all the cases routline hemoglobin, total and different count of WBC, 
urine deposits, blood sugar, urea and serum creatinine were estimated. 
 
GRADING OF SEVERITY 
 
    Patients were graded as follows: 
 Grade I :  Local cellulitis, regional lymph adenitis, normal 
clotting time. 
 Grade II: Prolonged clotting time + local features. 
 Grade III:        Presence of systemic bleeding + prolonged clotting 
time-15. 
 
 
WHOLE BLOOD COAGULATION TIME 
 
 Though there are various methods of assessing the clotting time, 
( the normal by Lee and White – 6- 9 minutes, by Dale & Laid -3-5 
minutes) the method selected for our study was that of Ulans, for 
practical reasons. By this method two ml of blood was kept undisturbed 
in a pyrex test tube (10cm tall and inside diameter 1cm). After 5 minutes 
test tube was gently tilted to 45 and tested for clotting. Procedure was 
repeated every minute until the blood clotted. The normal clotting time 
by this method was in the range of 9 to 15 minutes.35 The sample was 
left behind to assess the clot quality as described earlier. 
 
BLEEDING TIME 
 
 Bleeding time was estimated by Duke’s method. Here, a needle – 
prick was given on the tip of the finger, about one centimeter deep, and 
the blood blotted off. The time taken for the bleeding to stop was noted. 
Normal range: 3 to 5 minutes. 
 
PLATELET COUNT 
 
 The stain used was brilliant cresyl blue prepared by mixing 
0.3gms of brilliant cresyl blue crystals with one drop of formalin and 100 
ml of distilled water. Using a RBC pipette blood was taken upto the 0.5 
reading and brilliant cresyl blue fluid ( 1 in 200 dilution) till the 101 mark. 
It was left for two minutes and then charged with a cover slip into a 
neubars chamber. Platelets were seen as bluish pink spots. Normal 
range – 1.5 – 3 lakhs/cubic mm. 
 
 
 
BLOOD COLLECTION AND PROCESSING FOR COAGULATION 
PROFILE TEST 
 
  Blood withdrawn from a vein was mixed with 3.8% aqueous 
trisodium citrate in the ratio of 9 volumes of blood to 1 volume of citrate 
solution. (i.e., 1.8 ml of blood with 0.2 ml of sodium citrate). Blood was 
taken immediately to the laboratory. In case of delay, samples obtained 
were stored in a freezer at 4 degree Celsius. In the laboratory, 
centrifugation at 3000 rpm was done for 5 minutes. Resultant sample 
was used for the following tests. Control blood samples were also taken 
and similarly processed.36 
 
Samples were taken before administration of Anti snake venom. 
In a few selected cases samples were taken after anti snake venom 
administration. 
 
 
.  
PROTHROMBIN TIME 
 
 
   Although originally thought to measure prothrombin 
the test is now known to depend also on reactions with factors V, VII 
and X and fibrinogen concentration. Thus the name prothrombin time is 
not accurate. This test measures the effectiveness of extrinsic pathway. 
Test was done with both patient and then control plasma. 0.1 ml of 
plasma in glass tube was placed in a water bath at 37c for 3 – 5 
minutes and 0.2 ml of Liquiplastin reagent (Thromboplastin) was added. 
Time taken for the sample to clot was noted. Normal values depend on 
the thromboplastin used. The normal is 10 – 14 seconds over the 
control value 36 . 
 
ACTIVATED PARTIAL THROMBOPLASTIN TIME 
 
  This tests abnormalities of all coagulation factors except 
factors VII and XIII. It is especially sensitive for early stage of intrinsic 
pathway. With 0.1ml of test plasma 0.1ml of Liquicelin reagent solution 
was mixed for 3 minutes at 37c in water bath. 0.1 ml of prewarmed 
calcium chloride was added and stop watch started end pointed 
recorded. Abnormal values should exceed control value by 6 seconds. 
More than 10 seconds is definitely abnormal.36 
 
THROMBIN TIME 
 
  0.2ml of sample plasma was incubated at 37c for 2 
minutes. 0.1ml of thrombin time reagent was added and stop watch 
started. Clotting time was measured. Test is repeated in two test tubes 
with patients plasma and control plasma. 20 seconds and over are 
abnormal. Patients value should be within two seconds of control 
value.36 
 
FIBRIN DEGRADATION PRODUCT 
 
 
  The reagent used in this test was Dimertest  II latex 
reagents coated with mouse monoclonal Anti-D dimmer antibody. Serial 
dilutions of the test plasma were prepared. For 1:2 dilution, 100 
microlitres of plasma were added to 100 microlitres of phosphate buffer 
solution. For 1:4 dilution 100 microlitres of 1:2 dilution solution were 
added to 100 microlitres of 1:2 dilution solution were added to 100 
microlitres of phosphate buffer solution. This procedure was repeated to 
extend to the desired dilution. For each of the dilute solutions 20 
microlitres of plasma were added and mixed with reagent solutions. 
Slide was rotated gently for 3 minutes. At the end of 3 minutes 
agglutination is checked for . 
 Highest dilution in which visible agglutination occurs is taken as a 
titre. 
 
 
  
   INTERPRETATION OF RESULTS 
 
Plasma from normal individuals is not expected to agglutinate. 
 
 FIBRINOGEN 
 
  Reagents used: 1) Ammonium sulphate -13.3gms of 
ammonium and 1gm of sodium chloride in 100ml of distilled water. ph is 
adjusted by adding 10N NaOH. 
 
2) Normal saline – 9mg of sodium chloride in 1 litre of water. 
 
SAMPLE DILUTION TITRE APPROXIMATE 
    XL-FDP 
LEVELS (mg/1) 
 
UNDILUTED  
 
1:2 1:4 1:8 
0 Normal      -   -  -  - 
1 0.25 – 0.5  + - - - 
2 0.5 – 1 + + - - 
4 1 – 2 + + + - 
8 2 – 4 + + + + 
   TEST       BLANK 
 
0.5 ml plasma and 0.5ml Normal               1ml of normal saline added to 
 saline added to 9ml of      9ml of Ammonium sulphate 
ammonium sulphate solution 
 
Shake and read after 5 minutes with 420 filter. 
Result = test – blank = Blood fibrinogen in milligram% 
 (Normal 200 – 400mgm%) 
 
    
 
 
 
 
 
 
 
 
 
 
                   
                           ANALYSIS OF RESULTS 
 
GENERAL FEATURES 
 
   A total of 147 patients were admitted in Thanjavur 
medical college hospital general medical wards from july 2007 to 
October 2008 with either history or features suggestive of snake bite. Of 
the 147 patients 64 had features suggestive of hemostastic abnormality. 
Seven patients presented primarily with neurotoxic manifestation. One 
patient had hemostatic and neurotoxic abnormality. Rest of the 75 
patients had no features of envenomation. Another 117 patients were 
treated as unknown reptilian bite. Thus of 147 patients admitted with 
either history or clinical features suggestive of snake bite 48.9% were 
poisonous and 51.1% were nonpoisonous. Of the poisonous bite 89% 
had primary coagulation abnormality and 9.7% had neurotoxic 
manifestion and 1.3% both. 
 
   Of the 64 patients admitted with features for primary 
haemostatic disturbance fourty eight were selected at random for the 
study. The average age of the patients in our study was 38 yrs ranging 
from 7 yrs to 65 yrs. 
 
    
 43.52%
51%
Hemotoxic Neurotoxic Mixed Non-Poisonous
 
 
 
 
 
22.09%
52%
25%
Grade-I Grade-II Grade-III
 
The study population was separated into 3 categories Grades I, II and 
III according to clinical features and clotting time. Eleven patients 
belonged to grade I, 25 to Grade II, and another 12 to Grade III (22%, 
54%, 24%) respectively. These patients were subjected to various 
coagulation parameter assessment tests. Majority of the patients had 
bite on the lower limb – 63.6%. The incidence of bite in the upper limb 
was 36.4%. The average duration of hospital stay of the snake bitten 
individuals with clotting abnormality was 6 days, ranging from 3 to 31 
days. 
 
 
ASSESSMENT OF CHANGES IN COAGULATION PROFILE: 
 
 
  Blood for assessment of changes in coagulation were taken 
at the time of admission before therapy was started in patients who had 
definite features of envenomation, excluding neurotoxic manifestations. 
 
1. Clotting Time: 
 
Of the forty eight patients selected for study, 76% has 
prolonged clotting time at the time of admission. In another 
3 cases (6.2%) clotting time was normal at the time of 
admission, but turned abnormal in a period of 4-12hrs. 
Thus in total 82% of the patients had prolonged clotting 
time. 
 
2. Bleeding Time: 
 
Bleeding time was analysed in forty out of the total of 48 
cases. In all cases it was found to be normal, even in those 
cases who had systemic bleeding manifestatious in the 
form of haematuria, haematemesis and haemoptysis. The 
average bleeding time was found to be 2 – 6 minutes 
 
 
3. Platelet Count: 
 
Platelet count was found to be reduced in all cases 
belonging to both Grades II and III. The average platelet 
count was 97,486 cells/ cumm. Thus a 100% reduction was 
noted. The average count in Grade I was 2.3 Lakhs. 
 
 
 
 
4. Prothrombin Time: 
 
This test is done primarily to evaluate any abnormalilty in 
extrinsic pathway. It was done in ten out of eleven cases 
belonging to grade I [that is local features with normal 
clotting time]. The test was found to be normal in all but one 
patient. This patient who belonged to grade I with 
prolonged prothrombin time went on to develop abnormal 
coagulation profile over a period of six hours. Another two 
patients who ;had similar clinical condition showed a 
normal prothrombin time. 
 
In Grade II 21 out of 25 cases were evaluated for 
prothrombin time and in Grade III 10 out of 12 cases were 
tested. All these patients showed prolongation of 
prothrombin time denoting a 100% positivity. 
 
PT level assessed in patients following anti snake venom 
therapy showed a normalization by forty eight hours. 
 
 
 
 
5. Activated Partial Thromboplastin Time: 
 
APTT test is done to evaluate any abnormality in intrinsic 
pathway. Test was done in 10 out of 11 cases in Grade I 
were normal except for 1 patient who latter went on to 
develop abnormal coagulation features. The test done in 20 
patients of Grade II and 10 of Grade III were prolonged. 
Thus the test was 100% positive in patients belonging to 
Grades II and III. APTT was found to be prolonged up to a 
period of 48 hrs following ASV therapy 
 
 
6. Thrombin time: 
 
This test was done in eight  cases with Grade I 
envenomation. It was normal in all of them including those 
cases where PT and APTT were prolonged and patients 
later went on to develop abnormal coagulation. In grade II 
and III categories, tests were done in 20 out of 25 and 10 
out of 12 cases respectively. They showed 100% 
prolongation as in case of PT and APTT. The test returned 
to normal by 48 hrs. 
 
 7. Fibrin degradation products: 
 
This test detects fibrinolysis occurring as a primary or 
secondary phenomenon. This was done for 6 cases 
belonging to grade. I. All if them showed no evidence of 
fibrinolysis. In 16  cases belonging to grade II 64.9% 
showed positive results in a dilution of 0.5mg and 35.1% in 
a dilution of 1 to 2. Thus the test was 100% positive. In 
grade III patients, test done in 5 out 12 cases, eighty 
percent showed positivity in dilution 0.5 to 1 and the next 
20% in 1 to 2mg. hence the test was again 100% positive. 
 
 
8. Fibrinogen: 
 
Plasma fibrinogen was estimated in all patients. Patients 
belonging to Grade I showed an average level of 245.5mgs 
[Normal 200 to 400 mg / dl].fibrinogen levels studied in 
grade II category showed an average of 166.7mgs and in 
grade III 143.9mgs. Thus there was 100% reduction in 
fibrinogen levels in Grade II and III categories. 
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CORRELATION OF COAGULATION ABNORMALITY WITH THE 
TYPE OF SNAKE: 
 
  In 11 out of 48 patients [23%] the snake was killed and 
brought to the hospital and thus could be identified. The  77% sustained 
an unknown  bite which was later treated as snake bite based on clinical 
evaluation. Among the patients who identified the snake 72% was saw 
scaled viper bite. 18.3% identified the snake as Russell viper and one 
patient who expired had sustained a Krait bite. 
 
 
ANALYSIS OF SYSTEMIC BLEEDING MANIFESTATIONS IN SNAKE 
BITTEN INDIVIDALS: 
 
 
  A total 12 patients out of 48 had systemic bleeding. Out of 
them 33.33% presented with haematuria while 58.3% had gum bleeding 
and 25% of individuals had haemoptysis and 8.3% hemetemesis and 
8.3% epistaxis. 
 
 
 
ANALYSIS OF THE TIME INTERVAL BETWEEN SNAKE BITE AND 
ONSET OF COAGULATION ABNORMALITY: 
 
  The time of onset of abnormal coagulation was analysed 
based on two sets of findings. The first was based on the number of 
patients who had prolonged clotting time at the time of admission. 77% 
of patients had abnormal clotting time at the time of admission. The 
average time period between the bite and hospital admission was 7.15 
hours ranging from 2 hours to 12 hours. 
 
  The second group analysed has a set of three patients who 
had normal clotting time at the time of admission which become 
abnormal over a period of time. Two of them developed it in a period of 
6 hours and the third patient by 12 hours. Thus it was concluded, that 
the onset of abnormal coagulation occurred as early as 2 hours and late 
as twelve hours with a majority developing it in an average time of 
seven hours. 
 
  All patients who had prolonged clotting time at admission 
also had a prolonged PT, TT, and FDP. One patient who had initial 
normal clotting time and went on to develop abnormal coagulation had 
prolonged PT and APTT at the initial instance itself. 
CORRELATION OF CLINICAL SEVERITY WITH QUANTITATIVE 
COAGULATION TESTS: 
 
  Three quantitative tests namely FDP, platelet count and 
fibrinogen were analysed in relation to clinical severity. 
  FDP was negative in all patients belonging to grade I. In 
grade II patients, the test was positive in a dilution of 0.5 to 1 in 64.9% 
cases and 1 to 2 in 35.1%. In grade III, 80% showed a positive result in 
a dilution of 0.5 to 1 and 20% in a dilution of 1 to 2. Thus in conclusion 
FDP level did not correlate with the clinical severity assessment. 
   
Platelet count was normal in all patients belonging to Grade I with an 
average of 2.3 lakh/cumm. The average platelet count in grade II 
individuals was 1.01 lakh/cumm and grade III 90,400/cumm. Thus, 
though the platelet count was reduced in all snake bitten individuals with 
coagulation abnormality, it did not  
 correlate with severity of envenomation. 
 
  Blood fibrinogen analysis done in patients of grade I 
showed no reduction, the average level was 245mg/dl. Grade II patients 
had an average level of 166mg/dl and grade III 143 mg/dl. Thus the 
level of serum fibrinogen was found to be decreasing with severity of 
envenomation. 
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ANALYSIS OF THE TIME TAKEN FOR THE RETURN OF 
COAGULATION PROFILE TO NORMAL: 
 
  The time taken for clotting time to turn normal was 
analysed in grades II and III. For proper standardization of fixed 
regimen of ASV was used. Clotting time was repeated every second 
hourly and in certain cases at more frequent intervals. In grade II the 
average time taken for the clotting time to turn normal was 7.9 hours. 
The range was from 2 to 21 hours. In grade III individuals the average 
time taken for clotting time normalization was 18 hours, the range being 
4 to 24 hours. The average dose of ASV needed in grade II individuals 
was 13.8 vials (5 to 40), in grade III 15.5 (10 to 30 vials). 
  The time taken for the return of PT, APTT, TT, FDP, 
fibrinogen and platelet count to normal following ASV therapy was 
studied in four patients who had normal clotting time at admission 
though it was initially prolonged when managed in peripheral hospitals. 
PT, APTT and TT, fibrinogen FDP and platelet counts were abnormal in 
two patients in whom the test was done at forty eight hours. In two other 
patients in whom the test was done on 3rd and 5th day, only FDP 
fibrinogen and platelet were abnormal. PT, APTT and TT had 
normalized. Thus the average time taken for normalization of PT, APTT, 
TT was found to be 48 hours and while that taken for platelet count FDP 
and fibrinogen to return to normal was longer 
ANALYSIS OF RELATIONSHOP BETWEEN THE TIME OF BITE, 
INITIATION OF THERAPY, RETURN OF COAGULATION 
PARAMETERS TO NORMAL AND THE DEVELOPMENT OF 
COMPLICATIONS. 
 
TIME TO 
ONSET OF 
TREATMENT 
(HOURS)  
GRADE NUMBER 
OF 
CASES  
NUMBER 
OF 
CASE 
RENAL 
FAILURE
RETURN 
OF 
CLOTTING 
TIME TO 
NORMAL  
AVERAGE 
NO OF 
ASV 
G II 10 - 8.8 14.5  0-5 
GIII 3 - 9 15 
G II 8 2 8.7 14.5 5-10 
G III 5 1 11.6 17 
G II 4 2* 10 10.5 10-15 
G III  2  1 11 11.5 
G II 3 1* 7 8 > 15 
G III 2 1 20 15 
** (PATIENTS ADMITTED WITH ESTABLISHED RENAL 
FAILURE TREATED OUTSIDE TMCH) 
It is evident from analysis of the above table, that the time of onset of 
therapy correlate with the development of complications in hospital- 
treated individuals. The incidence of renal failure has been found to be 
high if treated late. 
 
   The return of clotting time to normal following therapy 
with ASV  correlate with the time period between bite and onset of treat 
ment and also by the severity of envenomation. 
 
 
ANALYSIS OF INCIDENCE OF RENAL FAILURE IN RELATION TO 
ALTERATION IN COAGULATION PROFILE: 
 
  In total 19% of the study population developed renal failure 
of which 11% belonged to grade I, 55.5% to grade II and 33.3% to 
grade III. Patients in grade I who developed renal failure had a normal 
coagulation profile. 
  55% of the renal failure was from grade II, but the important 
observation was 3 out of the 5 patients who developed renal failure in 
this group had developed the disease before hospitalization in thanjavur 
Medical College Hospital. They had been managed with low dose ASV 
(an average of 5 vials) in the peripheral centre. Only two of the twenty 
two patients belonging to grade II developed renal failure during hospital 
therapy. Thus excluding those patients who had established renal 
failure at the time of admission, only 9% of hospital treated individuals 
developed renal failure in Grade II. The average FDP level was 0.5 to 1 
mg/dl in these patients. The average platelet count was 1.2lakhs / 
cumm and fibrinogen level was 185mg / dl. 
  In grade III, 3 out of 12 patients (25%) developed renal 
failure despite hospital treatment. The FDP level in two patients was 0.5 
to 1 and one of them was 1 to 2 mg/dl. The average platelet count was  
85,000/cumm and fibrinogen level was 124 mg/dl. 
  Three patients in grade II were treated by peritoneal 
dialysis (one sitting) while one patient was managed conservatively. In 
grade III two patients were managed conservatively while one needed 
two sittings of peritoneal dialysis.  
  Thus in conclusion, the severity of envenomation correlated 
with the development of renal failure in hospital treatment individuals. 
As in case of severity, fibrinogen levelcorrelated well with development 
of renal failure than platelet count and FDP 
 
 
 
 
 
 
                                 
 
                                     DISCUSSION 
 
EPIDEMIOLOGICAL ASPECT 
 
    The cauvery basin, comprising the areas in 
and around thanjavur, is a highly fertile area. The primary occupation of 
the people in this area, for several generations has been agriculture. 
 
    This abundance of farmland, which is the 
natural habitat of snakes such as the viper has meant that there has 
been a constant high incidence of snake bite cases over the past 
several years presenting to our institution. Of these, the commonest 
presentation has been with hemostatic abnormalities and this has 
prompted us to conduct a study on the coagulation failure following 
snake bite. In an hospital analysis of the statistics for the period 2005 to 
2007 revealed that the maximum number of cases were admitted during 
the monsoon period. Hence this study was conducted during this 
period. 
 
    The incidence of snake bite and its severity is 
well known to increase during the rainy season. In North India, 80% of 
bites per annum occur between May and October, while in North Kerala 
it occurs between October to January. 16,17 
     A total of 147 cases were admitted following 
snake bite in this period. Of these, 48.9% had features of 
envenomation. 89% was hemotoxic, 9.7% was neurotoxic and 1.3% 
was of the mixed variety. It is known in India, out of 236 species of 
snakes, only 50 are poisonous. Commonly encountered snakes include 
krait, cobra, saw-scaled viper and Russell viper.2 Taking these into 
consideration, the incidence of envenomation has to be low compared 
to the total number of bites. Our study shows 48.9% of snake bite 
victims had envenomation features. This high incidence may be due to 
the fact that a large number of non-poisonous snake bite may have 
been treated at local hospital or, if referred here, may have been 
recorded under the separate category of unknown reptilian bite. 
 
    As we have mentioned already, the greater 
incidence of patients presenting with hemostatic abnormality (89%) 
compared to neurotoxic group (9.7%) may be related to the natural 
habitat of snakes, viper being the principal offender (farmland habitat). 
 
    Percentage of patients with bites in the lower  
 
 
 
limb in our study was 63.3% and upper limb 36.7%. This correlated with 
other studies as shown by Sawai  in 1974( lower                                                               
  limb bite – 72% ; upper limb bites -25% , 3% other part s).  
 
    The average duration of hospital stay in our 
study was 6 days (range – 3 to 31 days ). The reason for prolonged 
hospitalization included the development of complication like renal 
failure and gangrene secondary to compartmental syndrome. 
 
 
CHANGES OBSERVED IN COAGULATION PROFILE. 
 
 Clotting time 
 
   The study conducted by Reid reported 100% 
prolongation of clotting time in all cases of definite envenomation.11 In 
Orisa study 95% had a prolonged clotting time.30 6% of these developed 
abnormality after admission, 6 to 12 hours later. This emphasis the fact 
that local cellulitis and lymphadenitis is an important clue for viper bite. 
Cases that had local features but normal clotting time, also may have to 
be treated with ASV as they may later develop coagulation abnormality 
– as in 6% of our cases – or, may develop other complications such as 
acute renal failure (one case in our study). 3 patients had no local 
features but had prolongation alone cannot be taken as a 100% reliable 
indicator of hemotoxic envenomation. When clotting time was 
considered with local features, the specificity was significantly increased 
(especially viper bite) 
 
  Bleeding time 
 
    Only 10% showed prolonged bleeding time in 
the study conducted in Orissa.30 The incidence reported by Reid was 
5%  
 
    In our study, none of the patients including 
those with systemic bleed, had an abnormal bleeding time. We infer that 
though platelet abnormality may be a contributory factor, it is not the 
major cause of bleeding. 
 
  Platelet count 
 
    Studies by both Reid and Mohapathra (in 
Orissa) showed a reduction in platelet count in 95% and 93% 
respectively. 11,30.  Saini et al reported a 10% incidence of reduced 
platelet counts.33 We observed a reduced platelet count in all cases 
(average count – 97,486/cu. Mm.) with prolonged clotting time. However 
there was no significant correalation with severity. Even patients having 
mucosal bleeds (hematuria, hemetemesis) had only moderately 
reduced platelet counts (not sufficient to cause spontaneous bleeding ) 
and normal bleeding times. Hence, we conclude that the effect of direct 
vasotoxic toxin – “ hemorrhagin” – must be a significant factor in 
causing mucosal bleeding.22 
 
Prothrombin, activated partial thromboplastin & thrombin times. 
 
  Thrombin time, prothrombin time and activated partial 
thromoboplastin time were prolonged in all cases in the orissan study.30 
PT and TT were prolonged in all cases in Reid’s study. The test was 
found to be prolonged even in the 5% of cases where clotting time was 
normal. In our study the test was prolonged in all cases belonging to 
grades II and III envenomation (i.e., those with prolonged clotting times) 
in patients with normal clotting time, the test was prolonged in only one 
of the eleven (9%). The significant finding was that this case was one 
among the three that went on to develop prolongation of the clotting 
time latter. In conclusion, as with other studies, PT, APTT and TT have 
shown prolongation in all cases with prolonged clotting time, indicating 
that the venom activates both intrinsic and extrinsic pathways equally. 
In patients with normal clotting times, the test was prolonged in all 
cases in the orissan study30 but in our case only one of the patients 
belonging to this category showed similar results, and this patient went 
on to develop clotting abnormalities later. It has been stated that while 
the clotting time may be normal even when clotting factors in the blood 
are at 1% of normal amount, PT and APTT are prolonged below a value 
of 6% of normal itself 37. This suggests that the latter tests detect 
hemotoxicity earlier: however, further large scale studies, with more 
number of patients are needed to establish this. The average time taken 
for the normalization of these tests in our study was found to be 48 
hours. 
 
Fibrin degradation products (FDP) 
 
  FDP was increased in all cases with prolonged clotting time 
but not in the group with normal clotting times, even in the presense of 
other features of envenomation. The orissan study showed that all the 
patients had increased FDP.30 We found no correlation between the 
severity of envenomation and FDP levels. Thus fibrinolysis (either 
primary or secondary) is the mechanism responsible for prolongation of 
clotting time and the resultant complications in viper bites. 
 
 
 
 
Fibrinogen 
 
  Blood fibrinogen was reduced in all patients belonging to 
Grades II & III (average values 166.7 mg% and 143.9 mg% 
respectively). The reduction was proportionate to the severity. The other 
studies reported reduced fibrinogen in all cases with prolonged clotting 
time 11,30 
 
  In this study, we have attempted to find out which of 
disseminated intravascular coagulation or primary fibrinolysis was the 
underlying mechanism responsible for the coagulation abnormality. 
 
  Several international studies, including the one by Reid, 
and an Indian study by Mohapathra et al pinpointed DIC as the primary 
mechanism.11,30. However, a study by Saini et al involving 30 cases of 
snake bite, reported fibrinolysis as the primary mechanism33. . Primary 
fibrinolysis, a relatively rare condition, if diagnosed by the presence of a 
combination of a normal platelet count, early lysis of formed clots, 
marked elevation of FDP and negative tests for fibrin monomers ( as 
tested by the protamine sulphate test). However these findings were 
absent in our patients and hence we favour DIC as the primary 
mechanism.  
 
  To summarise the changes in coagulation profile, it is found 
that snake venom activates both intrinsic and extrinsic pathways 
equally, with DIC as the main factor responsible for bleeding. This 
seems to suggest a role for the usage of heparin in the early phase of 
therapy. Platelet abnormalities may be a contributory mechanism, but 
are not primarily responsible. Spontaneous mucosal bleeds observed 
may be due to directly vasotoxic hemorrhagin. 
 
Common snake bites presenting as bleeding diathesis 
 
   Only 23% of our patients could identify the snakes  of 
which 72.72% were saw-scaled viper bites, 18.18% Russell  viper, and 
9% krait. Similar distributions have been reported by other workers.11 
The majority of victims (77%) could not identify the snake they were 
bitten by, and hence, as suggested by Reid, we would like to emphasise 
that the treatment should be based more on the clinical presentation 
than on the identification of the snake. 
 
Common forms of systemic bleeding 
 
   In this study 33.3% of patients with systemic bleeding 
had hematuria, 58.3% Gum bleeding and the rest had hemoptysis or 
haemetemesis. Other common forms cited in literature are hemoptysis 
(Reid), and hematuria (virmani et al from Kashmir).11 
 
Onset of coagulation abnormality 
 
   Practically, it is quite difficult to predict the exact time 
of onset of coagulation abnormality in a given case. As discussed 
earlier, the PT and APTT may be prolonged even before over 
prolongation of the clotting time. 
 
   We used those patients who developed clotting 
abnormalities after admission to calculate the shortest (2hours ) and the 
longest (12 hours) intervals between bite and onset of clotting 
abnormality. 
 
   The average interval, calculated by including the data 
from patients with bleeding diathesis at admission, was 7.15 hours. 
 
 
Quantitative tests in relation to clinical severity 
 
   The fibrinogen level showed some correlation with 
clinical severity, with the level being 166 mg% in Grade II and 143 mg% 
in Grade III patients. As in other studies, none of the other tests showed 
any correlation, including FDP estimation and platelet counts. 
 
Time taken for normalization of clotting time 
 
   Reid reported that the clotting time returned to 
normal in 9 hours with specific antiserum, and 24 hours with polyvalent 
serum. In our study fixed adequate doses of polyvalent serum alone 
were used and we found the average time for normalization to be 7.9 
hours in Grade II and 18hours in Grade III envenomation. The time 
taken for TT,APTT and PT to return to normal was 48 hours, similar to 
the findings in the Orissan study. For FDP fibrinogen and platelet counts 
to return to normal, it took 3 to 4 days approximately. 
 
Relationship between time of starting treatment development of 
complications, and normalization of clotting time 
 
    It was Reid who originally proved that the 
coagulation profile returned to normal rapidly with therapy, regardless of 
the time elapsed before the start of treatment11. The results of our study 
suggest that both the probability of complications and the time taken to 
achieve normalization of coagulation both depended on the severity of 
the bite, and the time elapsed before starting of treatment. On this 
basis, and in accordance with an article published in the Lancet in 1968 
18. concluded that ASV can be effective even if given late, and hence 
that there is no time limit for starting ASV therapy. 
 
Renal failure and its relationship to clotting abnormalities 
 
    Our study showed the incidence of renal failure 
is 19%. In which grade II and grade III showed more incidence.  The 
distribution according to grades showed an increasing incidence in the 
more severe grades from I to III . This points to a direct role for 
coagulation abnormality in the pathogenesis of renal failure. 3 Cases 
were admitted in established renal failure, after receiving treatment 
outside. One patient belonging to Grade I also developed renal failure, 
suggesting a direct effect of snake venom on the kidneys was 
operational in this case. Among the quantitative tests, only fibrinogen 
depletion and low platelet counts correlated with the development of 
renal failure. 
 
 
 
 
 
 
                                C O N C L U S I O N S 
 
1. Hemotoxic envenomation was the commonest form of snake 
bite poisoning  seen in this study. 
2. Most of the bites involved the lower limbs 
3. Saw – Scaled viper was the commonest snake causing 
coagulation abnormality while Krait was the most poisonous ( 
in terms of mortality) 
4. Gum bleeding was the commonest form of systemic bleed 
observed 
5. In the diagnosis of hemotoxic envenomation, the presence of 
local signs plus a prolonged clotting time had a sensitivity of 
100% 
6. Disseminated intravascular coagulation appeared to be the 
primary mechanism responsible for coagulation abnormality 
7. Mucosal bleeding was most probably due to the direct 
vasotoxic action of hemorrhagin since reduction of platelet 
count in most cases was only moderate and bleeding times 
were uniformly normal 
8. Snake venom acts on both intrinsic and extrinsic pathways of 
coagulation as all cases showed prolongation of both 
prothrombin and activated partial thromboplastin times. 
9. Fibrinolysis is an important component of coagulation 
abnormality in snake bite as evidenced by reduced fibrinogen 
and presence of fibrin degradation products. 
10. Onset of coagulation abnormality occurred as early as two 
hour and as late as twelve hours following snake bite 
11. Prothrombin and Activated partial thromboplastin time 
appears to be prolonged earlier than clotting time – this needs 
further confirmation 
12. Among the quantitative coagulation tests only fibrinogen 
level correlated with the severity of envenomation compared to 
fibrin degradation products and platelet count. 
 
13. The time interval between the bite and initiation of 
treatment was found to be related to time taken for 
normalization of the coagulation abnormality or to the 
development of complications in this study. 
14. Following ASV therapy, the time taken for normalization of 
clotting time was found to be around 8 hours in Grade II and 
18 hours in Grade III individuals. 
15. Direct effect of venom on the kidney was also found to play 
a role a longwith disseminated intravascular coagulation in the 
causation of renal failure. 
 
                     S U M M ARY 
 
  Hemotoxic envenomation following saw –scaled viper bite 
was the commonest presentation in this study. The temporal pattern of 
coagulation abnormalities and their response to treatment were 
analysed. The severity of the bite was the most important factor in 
decicing the outcome, and disseminated intravascular coagulation was 
responsible for the majority of coagulation abnormalities. The findings 
suggest that early, adequate doses of ASV and anticipation of the 
complications of disseminated intravascular coagulation are the most 
significant aspects of management. Monitoring the coagulation status 
with the help of the test quoted in this study may increase our ability to 
diagnose coagulation abnormalities at an earlier stage, and thus may 
improve the management of snake bitten patients. 
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                                                  PROFORMA 
 
 
   NAME:                                         AGE:                        SEX:                 IP NO: 
 
 
   UNIT   :                                        DOA:                       TIME:                 DOD  : 
 
 
DETAILS  OF BITE: 
 
 
DATE:                                         TIME:                            SITE: 
 
 
FIRST AID:                                  Tourniquet --  Yes / No. 
 
                                                         Incision --   Yes / No. 
 
 
SNAKE:                                       SPECIES:                                   CONFORMED—YES/ NO. 
 
 
FEATURES  OF ENVENOMATION:   
 
 
LOCAL :                                     Fang marks -- Yes / No. 
 
                                                   Cellulitis    --    Yes / No. 
 
                                                    Regional   --    Yes / No. 
 
                                                Lymphadinitis --  Yes / No. 
 
 
SYSTEMIC:                             Hematuria / Hemetemesis / Hemoptysis 
 
                                                Epistaxis / Gum bleeding /  Others. 
 
                                                Neurological – Ptosis/  Ophthalmology. 
 
                                                Dysphagia / Dysphonia. 
 
 
OTHER SYSTEMS:              Pulse:                       BP:                        Resp.Rate: 
 
 
GRADE OF SEVERITY:  I  /  II  /  III. 
 
 
RENAL FAILURE:    YES / NO. 
 
PERITONEAL /  HEMODIALYSIS:                                   NO. OF SITTINGS: 
 
 
 
 
COAGULATION PROFILE: 
 
                   TEST                                                             DATE / TIME: 
 
Clotting time: 
 
Bleeding time: 
 
Platelet count: 
 
Prothrombin: 
 
APTT: 
 
Fibrin Degradation Products : 
 
Thrombin time plasma fibrinogen: 
 
 
OTHER INVESTIGATION: 
 
                TEST                                                              DATE / TIME: 
 
Hemoglobin: 
 
PCV: 
 
Urine deposits: 
 
Urea: 
 
Creatinine: 
 
S. Cholestrol: 
 
 
HOSPITAL COURSE: 
 
DATE /  TIME:                                  ASV:                           C T:                 OTHERS: 
 
 
 
 
 
TIME TO NORMALISATION OF CLOTTING TIME: 
 
 
 
RECURRENCE OF COAGULOPATHY :   YES /  NO. 
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                                                                                                                     MASTER CHART 
 
 
 
 
 
s Name X Ag Ip B Si Gd Assf Sy Ct Bt Plt Pt Ap Fdp Tt Fib Ud Ab Aa F P Bni Nt 
1 Krishnamoorthi M 37 1005674 U LF G2 - - ID 3.4 110000 22 40 0.5-
1 
35 109 No 
rbc 
30 0 - - 4.5 21 
2 Sumithra F 24 1009224 U LF G2-
1 
- - 10’ 2.1 210000 14 38 0.5-
1 
34 190 No 
rbc 
0 0  - 5.0 12 
3 Samikanna M 57 1005708 U LF G2 - - ID 4.1 90000 25 40 0.5-
1 
25 150 No 
rbc 
20 2 - - 14 15 
4 Muthukumar M 40 1005694 S RF G3 SHK EP ID 5.3 11000 20 30 - 37 160 No 
rbc 
15 0 + - 3.5 7 
5 Anjali F 50 1004254 U LF G1 - - 7’ 5.4 198000 14 38 0 18 220 No 
rbc 
20 0 - - 1  
6 Muniandi M 35 1005685 U RA G3 SHK GB ID 4.2 88000 18 38 - 32 168 Rbc+ 20 0 + - 7.5 6 
7 Balamurugan M 18 1005643 U LF G2 - - ID 3.1 94000 18 32 .5-1 32 122 No 
rbc 
30 10 + - 14 7 
8 Jayaperumal M 35 1008922 S RF G2 - - ID 4.1 80000 21 38 1-2 40 - No 
rbc 
10 0 - - 18 4.5 
9 Thangavel M 65 1010580 U RF G2 - - ID 2.1 85000 25 30 - 36 165 No 
rbc 
10 0 - - 13 6.5 
10 Anthoni samy M 52 1010598 R LF G2 - - ID 3.1 93000 - - - - 240 No 
rbc 
20 3 - - 2 5 
11 Mahendran M 20 1008882 S LA G3 - GB ID 1.5 110000 24 32 .5-1 34 188 Rbc+ 15 3 - - 4 8 
12 Agoran M 45 1010556 U RF G2 - - ID 1.2 100000 22 30 - 28 201 No 
rbc 
40 10 - - 7 14 
13 Rajendran M 45 1010928 U LF G3 - HP ID 3.4 100000 16 36 - 30 109 No 
rbc 
20 0 - - 17 24 
14 Dharmajan M 50 1012639 S LF G3 - GB ID 0 120000 22 40 .5-1 40 - rbc 20 0 - - 7 24 
15 Venkatesh M 48 1012960 U RF G2 - - ID 0 96000 30 35 1-2 30 180 No 
rbc 
10 0 - - 5.5 8 
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16 Rajendran M 30 1013022 U RF G2 - - ID 3.4 90000 20 40 1-2 30 175 No  
rbc     
10 0 + - 3 4 
17 Janaki F 35 1004298 U RF G1 - - 12’ 0 292000 14 18 0 18 275 No 
rbc 
2 0 - - 2.5 - 
18 Duraisamy M 45 1012949 U RF G2 - - ID 4.4 98000 18 30 .5-1 40 267 No 
rbc 
30 0 + - 1 7 
19 Savithri F 28 1013311 S LF G2 - - ID 2.1 96000 20 30 .5-1 40 - No 
rbc 
10 0 - - 48 6 
20 Mohan M 43 1005430 U RF G1 - - 6’ 0 240000 14 20 0 17 240 No 
rbc 
10 0 - - 1.5 - 
21 Veramathy M 65 1013464 U RA G2 - - ID 1.5 110000 24 30 - 30 150 No 
rbc 
10 0 + - 12 8 
22 Rajkumar M 33 1005391 U RA G1 - - 11’ 2.3 210000 14 18 - - 220 No 
rbc 
5 0 - - 2 -s 
23 Dhangarthy M 40 1013482 U RF G2 - - ID 4.1 90000 - - - - 170 No 
rbc 
15 0 - - 8 12 
24 Rajkumar M 33 1005391 U LA G1 - - 8’ 2.2 - - - - - - No 
rbc 
5 0 - - 3 - 
25 Karuppayya M 43 1005438 S RF G2 - - 8’ 3.2 90000 18 26 1-2 22 160 No 
rbc 
0 0 + 1 4 - 
26 Kannan M 23 1005447 U RA G1 - - 5’ 4.1 260000 14 18 - 18 240 No 
rbc 
5 0 - - 3 - 
27 Rajendran M 36 1005467 U RA G1 - - 7’ 2.1 180000 14 16 0 16 240 No 
rbc 
13 0 - - 4 12 
28 Krishnan M 38 1005452 U RA G1 - - 3’ 3.1 220000 18 28 0 16 220 No 
rbc 
10 0 + - 3 3 
29 Asok kumar M 40 1008867 U LF G1 - - 4’ 2.2 240000 14 16 - 18 260 No 
rbc 
3 0 - - 15 - 
30 Chithravel M 42 1008873 U RA G1 - - 4’ 3.2 300000 14 16 - - 280 No 
rbc 
5 0 - - 4 - 
31 Vinod M 7 1003904 U RF G2 - - ID 3.4 90000 20 40 1-2 30 175 No 
rbc 
 
10 0 + - 3 4 
Page 3 of 4 
 
32 Eswari F 7 1005067 U RF G1 - - 12’ 0 292000 14 18 0 18 275 No  
rbc  
2 0 - - 2.5 - 
33 Thirumurugan M 18 995470 U LF G3 - HP ID 4.1 52000 - - - - 148 No 
rbc 
20 10 - - 6 10 
34 Govindaraj M 50 996226 U RF G3 - GB ID 4.1 94000 20 38 .5-1 28 - Rbc+ 11 0 - - 10 12 
35 Karuppayyan M 38 997940 U RF G2 - - ID 4.1 88000 18 - - - 168 No 
rbc 
10 0 - - 1 11 
36 Anandan M 19 1000611 S LA G3 - GB ID 0 120000 - - - - 164 No 
rbc 
20 0 - - 4 12 
37 Chandrasekar M 26 1000552 U RF G2 - - ID 2.1 100000 14 38 .5-1 26 210 No 
rbc 
10 20 - 1 3 - 
38 Shammugan M 65 1001379 U RF G2 - - ID 4.1 99000 20 38 .5-1 40 75 No 
rbc 
10 0 - - 8 6 
39 Paramasivan M 60 1002250 U RF G2 - - ID 0 - 21 33 1-2 23 83 No 
rbc 
10 0 - - 7 4 
40 Rajendran M 40 1002440 K LF G2 - - ID 2.4 90000 - - - - 194 No 
rbc 
10 0 -
- 
- 7 10 
41 Nagaraj M 54 1003185 U RF G3 SHK GB ID 4.1 88000 24 35 1-2 36 110 No 20 0 + - - - 
42 Murugesan M 36 1003156 U RF G3 - HP ID 0 90000 22 30 .5-1 34 152 No 
rbc 
10 0 - - 6 12 
43 Ganesan M 39 1004145 R LA G3 - HM ID 0 110000 20 34 - 30 144 No 
rbc 
10 0 - - 14 8 
44 Vellayan M 50 1004115 U RA G3 - GB ID 4.1 80000 22 38 - 34 136 No 10 30 - 2 8 4 
45 Shanmugan M 25 1001530 U RA G2 - - ID 1.5 100000 20 34 1-2 28 - No 
rbc 
10 0 - - 2 4 
46 Pugalenthi M 41 1004063 U LF G2 - - ID 3.1 110000 22 32 .5-1 34 150 No 
rbc 
15 0 - - 2 16 
47 Punnathidasan M 30 1004160 S RF G2 - - ID 4.1 90000 - - - - 170 No 
rbc 
15 0 - - 8 12 
48 Tamilvarnan M 23 1004165 U RA G2 - - ID 1.5 110000 24 30 - 30 150 No 
rbc 
10 0 - - 12 8 
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                                                                           ABBREVATIONS 
                   
                   S- serial number             M- male               F- female           Si- site       B-bite          X-sex 
                   Ip- inpatient number       U-unknown         K-krait                 R-russel viper               S-saw scale viper 
                   LF-left foot                      Grd-grade         RF-right foot         LA-left arm                   RA-right arm 
                   G1-grade one                 G2-grade two   G3-grade three                                           Syb-systemic bleed 
                   Epx-epistaxis                 Ptos-ptosis       HM-hemetemesis                                        F-renal failure 
                   P-peritoneal dialysis       HP-hemoptysis   ID- in definite     Assf-associated features 
                   Plt- platelet count  in lakhs                        Tt-thrombin time in seconds 
                   Bt- bleeding time in minutes                      Ct-clotting time in minutes 
                   Fdp-fibrin degradation products                 Fib-fibrinogen mg% 
                   UD-urine deposits                                       Pt-prothrombin time in seconds 
                   Ap-activated partial thromboplastin time in seconds 
                   Bni-bite needle interval in hours                  Aa-number of ASV given after clotting time normalization 
                   Ab- number of ASV vials given before clotting normalization 
                   Nt- normalization o clotting time in hours after ASV therapy 
                                     
